Agios Pharmaceuticals | Los Gastos De Explotación



Operating Expenses Cambio Fecha
AbbVie USD 16.59B 5.96B 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Arrowhead Research USD 163.91M 1.71M 2024-12
Astellas Pharma JPY 633.6B 214.16B 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Bayer EUR 8.2B 5.59B 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Daiichi Sankyo JPY 423.43B 70.8B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Exelixis USD 403.55M 82K 2025-01
Gilead Sciences USD 5.12B 1.54B 2024-12
GlaxoSmithKline GBP 7.42B 402M 2024-12
Incyte USD 877.18M 114.6M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
Merck USD 11.33B 1.4B 2024-12
Moderna USD 2.21B 280M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Novartis USD 10.15B 579M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Agios Pharmaceuticals Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.